Heidelberg Pharma DB:HPHA 주식 보고서 Heidelberg Pharma AG
DB:HPHA 주식 보고서
HPHA 주식 개요 하이델베르그 파마 AG는 독일, 기타 유럽 국가, 미국 및 전 세계에서 종양학 및 항체 표적 아마니틴 접합체(ATAC)에 주력하는 바이오 제약 회사입니다.
가격 내역 및 성능
다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Heidelberg Pharma 과거 주가 현재 주가 €2.38 52주 최고치 €3.97 52주 최저치 €2.18 베타 -0.36 11개월 변경 -4.42% 3개월 변경 사항 -0.42% 1년 변경 사항 -10.53% 33년 변화 -58.39% 5년 변화 13.33% IPO 이후 변화 -95.54%
최근 뉴스 및 업데이트
Third quarter 2024 earnings released: €0.13 loss per share (vs €0.002 profit in 3Q 2023) Oct 11
Second quarter 2024 earnings released: €0.086 loss per share (vs €0.20 loss in 2Q 2023) Jul 12
New major risk - Financial position May 02
First quarter 2024 earnings released: €0.10 loss per share (vs €0.14 loss in 1Q 2023) Apr 26
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 26
Price target increased by 14% to €8.85 Mar 08 더 많은 업데이트 보기
Third quarter 2024 earnings released: €0.13 loss per share (vs €0.002 profit in 3Q 2023) Oct 11
Second quarter 2024 earnings released: €0.086 loss per share (vs €0.20 loss in 2Q 2023) Jul 12
New major risk - Financial position May 02
First quarter 2024 earnings released: €0.10 loss per share (vs €0.14 loss in 1Q 2023) Apr 26
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 26
Price target increased by 14% to €8.85 Mar 08 Heidelberg Pharma AG to Report First Half, 2024 Results on Jul 11, 2024
New minor risk - Share price stability Dec 05
Price target decreased by 13% to €7.75 Oct 25
Third quarter 2023 earnings released: EPS: €0.002 (vs €0.14 loss in 3Q 2022) Oct 13
New major risk - Revenue and earnings growth Oct 11
Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101 Sep 19
Second quarter 2023 earnings released Jul 14
Heidelberg Pharma Ag Announces Executive Changes May 09
Price target decreased by 19% to €8.87 Apr 27
Price target decreased by 19% to €8.87 Apr 12
No longer forecast to breakeven Mar 28
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 27
Price target decreased by 8.0% to €10.30 Feb 07
Third quarter 2022 earnings released: €0.14 loss per share (vs €0.17 loss in 3Q 2021) Oct 14
Second quarter 2022 earnings released: €0.04 loss per share (vs €0.22 loss in 2Q 2021) Jul 13
Heidelberg Pharma AG Provides Earnings Guidance for the Year 2022 Jul 13
First quarter 2022 earnings: EPS misses analyst expectations May 01
Price target increased to €10.78 Mar 03 Heidelberg Pharma AG announced that it expects to receive €36 million in funding Feb 19
Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma Feb 15
Third quarter 2021 earnings released: €0.17 loss per share (vs €0.096 loss in 3Q 2020) Oct 08
Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US Sep 09
CEO, CFO & Member of the Executive Management Board Jan Schmidt-Brand has left the company Sep 03 Heidelberg Pharma AG Provides Financial Guidance for 2021
Forecast to breakeven in 2023 Jul 12
Second quarter 2021 earnings released: €0.22 loss per share (vs €0.17 loss in 2Q 2020) Jul 09
Heidelberg Pharma to Present Its Proprietary ATAC Technology Jun 18
First quarter 2021 earnings released: €0.20 loss per share (vs €0.16 loss in 1Q 2020) May 01
Heidelberg Pharma AG Reaffirms Earnings Guidance for 2021 Apr 29
Full year 2020 earnings released: €0.61 loss per share (vs €0.36 loss in FY 2019) Mar 27
Heidelberg Pharma AG Provides Earnings Guidance for the Year 2021 Mar 26
Heidelberg Pharma AG Heidelberg Pharma Expands Management Team Mar 03
New 90-day high: €8.28 Feb 17
Heidelberg Pharma AG and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine Feb 11
Price target raised to €6.52 Feb 08
Heidelberg Pharma AG Announces FDA Allows the Company to Start A Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 Feb 05 Heidelberg Pharma AG, Annual General Meeting, May 18, 2021
New 90-day high: €5.32 Dec 04
New 90-day high: €4.88 Nov 16
Heidelberg Pharma AG Announces Several Presentations of Research Results on ATAC Technology At the ASH Annual Meeting 2020 Nov 06
New 90-day low: €3.55 Oct 21
Heidelberg Pharma AG Updates Financial Guidance for the Year 2020 Oct 10
Third quarter earnings released Oct 09
New 90-day low: €3.83 Sep 29
New 90-day low - €3.90 Aug 13 주주 수익률 HPHA DE Biotechs DE 마켓 7D -4.8% -2.2% 1.1% 1Y -10.5% -17.1% 13.5%
전체 주주 수익률 보기
수익률 대 산업: HPHA 지난 1년 동안 -17.1 %를 반환한 German Biotechs 산업을 초과했습니다.
수익률 대 시장: HPHA 지난 1년 동안 13.5 %를 반환한 German 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is HPHA's price volatile compared to industry and market? HPHA volatility HPHA Average Weekly Movement 8.1% Biotechs Industry Average Movement 5.8% Market Average Movement 4.7% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: HPHA 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: HPHA 의 주간 변동성 ( 8% )은 지난 1년 동안 안정적이었지만 여전히 German 의 75%보다 높습니다. 주식.
회사 소개 하이델베르크 제약은 독일, 기타 유럽 국가, 미국 및 전 세계에서 종양학 및 항체 표적 아마니틴 접합체(ATAC)에 중점을 두고 있는 바이오 제약 회사입니다. 주요 제품 후보로는 재발성 또는 불응성 다발성 골수종 치료를 위한 임상 1상/IIa상 연구 중인 HDP-101이 있습니다. 비호지킨 림프종 치료를 위한 HDP-102, 전이성 거세 저항성 전립선암 치료를 위한 ATAC 후보물질인 HDP-103, 위장관 종양 치료를 위한 HDP-104를 개발 중입니다.
자세히 보기 Heidelberg Pharma AG 기본 사항 요약 Heidelberg Pharma 의 수익과 매출은 시가총액과 어떻게 비교하나요? HPHA 기본 통계 시가총액 €114.18m 수익(TTM ) -€18.77m 수익(TTM ) €8.47m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) HPHA 손익 계산서(TTM ) 수익 €8.47m 수익 비용 €1.66m 총 이익 €6.81m 기타 비용 €25.58m 수익 -€18.77m
주당 순이익(EPS) -0.40 총 마진 80.41% 순이익 마진 -221.51% 부채/자본 비율 0%
HPHA 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
